Viewing stories from April, 2012

30 April 2012
Appendix 4C - Quarterly Cashflow report

Starpharma today released its Appendix 4C - Quarterly Cashflow report for the period ended 31 March 2012.

Read More

16 April 2012
Shareholder Update: April 2012

In this issue:

› Starpharma commences pivotal phase 3 VivaGel® BV treatment trials

› Starpharma continues to build momentum as a leader in the sector

› Starpharma improves efficacy of leading chemotherapy drug docetaxel with dendrimers in breast cancer model

› Nanobiotechnology to reach $6 billion by 2017

 

Download: Shareholder Update: April 2012 ( pdf file, 1MB)

Read More

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.